NEXI Key Statistics, Chart & Performance
The current stock price of NEXI is 3.93 USD. In the past month the price increased by 35.99%. In the past year, price decreased by -41.99%.
NEXI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About NEXI
Company Profile
NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. The company is headquartered in Gaithersburg, Maryland and currently employs 6 full-time employees. The company went IPO on 2021-02-12. The firm is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The firm provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The firm is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Company Info
NEXIMMUNE INC
9119 Gaither Road
Gaithersburg MARYLAND 20878 US
CEO: Scott Carmer
Employees: 6
Phone: 13018259810
NEXIMMUNE INC / NEXI FAQ
What does NEXI do?
NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. The company is headquartered in Gaithersburg, Maryland and currently employs 6 full-time employees. The company went IPO on 2021-02-12. The firm is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The firm provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The firm is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
What is the current price of NEXI stock?
The current stock price of NEXI is 3.93 USD. The price increased by 70.13% in the last trading session.
Does NEXIMMUNE INC pay dividends?
NEXI does not pay a dividend.
What is the ChartMill rating of NEXIMMUNE INC stock?
NEXI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting NEXI stock to perform?
7 analysts have analysed NEXI and the average price target is 2.04 USD. This implies a price decrease of -48.09% is expected in the next year compared to the current price of 3.93.
What is NEXIMMUNE INC worth?
NEXIMMUNE INC (NEXI) has a market capitalization of 5.38M USD. This makes NEXI a Nano Cap stock.
When does NEXIMMUNE INC (NEXI) report earnings?
NEXIMMUNE INC (NEXI) will report earnings on 2024-08-07, after the market close.
NEXI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NEXI. When comparing the yearly performance of all stocks, NEXI is a bad performer in the overall market: 83.05% of all stocks are doing better.
NEXI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NEXI. The financial health of NEXI is average, but there are quite some concerns on its profitability.
NEXI Financial Highlights
Over the last trailing twelve months NEXI reported a non-GAAP Earnings per Share(EPS) of -66.25. The EPS decreased by -245.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -287.63% | ||
| ROE | -871.66% | ||
| Debt/Equity | 0 |
NEXI Forecast & Estimates
7 analysts have analysed NEXI and the average price target is 2.04 USD. This implies a price decrease of -48.09% is expected in the next year compared to the current price of 3.93.